US Drug Recall Register

FDA Drug Recalls

11,815 recalls · Class II, newest first

Class II · Moderate risk Terminated

Ropinirole

Reason cGMP deviations

Direct Rx NDC 72189-0364-30 D-0479-2023
Class II · Moderate risk Terminated

Ropinirole

Reason cGMP deviations

Direct Rx NDC 72189-0364-30 D-0478-2023
Class II · Moderate risk Terminated

Finasteride

Reason cGMP deviations

Direct Rx NDC 61919-0733-90 D-0477-2023
Class II · Moderate risk Terminated

Montelukast Sodium Tablets

Reason cGMP deviations

Direct Rx NDC 61919-0009-30 D-0476-2023
Class II · Moderate risk Terminated

Jardiance

Reason Labeling: Label Mix-up

Boehringer Ingelheim Pharmaceuticals, Inc. NDC 0597-0153-30 D-0468-2023
Class II · Moderate risk Terminated

Calcitonin Salmon Nasal Spray

Reason Failed Impurities/Degradation Specifications and Subpotent Drug: High Out of Specification results for a known and unknown impurity as well as low Out of Specification results for assay.

Endo Pharmaceuticals, Inc. NDC 49884-161-11 D-0475-2023
Class II · Moderate risk Terminated

Clobazam Tablets

Reason CGMP Deviations: Potential risk of Cross Contamination

Breckenridge Pharmaceutical, Inc NDC 51991-901-01 D-0463-2023
Class II · Moderate risk Terminated

Clobazam Tablets

Reason CGMP Deviations: Potential risk of Cross Contamination

Breckenridge Pharmaceutical, Inc NDC 51991-900-01 D-0462-2023
Class II · Moderate risk Terminated

Alprazolam Tablets

Reason CGMP Deviations: Potential risk of Cross Contamination

Breckenridge Pharmaceutical, Inc NDC 51991-0707-01 D-0461-2023
Class II · Moderate risk Terminated

Alprazolam Tablets

Reason CGMP Deviations: Potential risk of Cross Contamination

Breckenridge Pharmaceutical, Inc NDC 51991-0706-01 D-0460-2023
Class II · Moderate risk Terminated

Alprazolam Tablets

Reason CGMP Deviations: Potential risk of Cross Contamination

Breckenridge Pharmaceutical, Inc NDC 51991-0705-01 D-0459-2023
Class II · Moderate risk Terminated

Alprazolam Tablets

Reason CGMP Deviations: Potential risk of Cross Contamination

Breckenridge Pharmaceutical, Inc NDC 51991-0704-01 D-0458-2023
Class II · Moderate risk Terminated

Heparin Sodium

Reason Subpotent Drug: low Anti-Factor IIa potency.

B. Braun Medical Inc NDC 0264-9587-20 D-0434-2023
Class II · Moderate risk Terminated

Heparin Sodium Injection

Reason Labeling: Not elsewhere classified

Sagent Pharmaceuticals Inc D-0435-2023
Class II · Moderate risk Terminated

Activator Concentrate

Reason CGMP DEVIATIONS

Ecometics, Inc. D-0451-2023
Class II · Moderate risk Terminated

Nose Better Gel

Reason CGMP DEVIATIONS

Ecometics, Inc. D-0450-2023
Class II · Moderate risk Terminated

Soltice Quick-RUB

Reason CGMP DEVIATIONS

Ecometics, Inc. D-0449-2023
Class II · Moderate risk Terminated

Vencedor medicated balm

Reason CGMP DEVIATIONS

Ecometics, Inc. D-0447-2023
Class II · Moderate risk Terminated

Alcolado Relampago

Reason CGMP DEVIATIONS

Ecometics, Inc. D-0446-2023
Class II · Moderate risk Terminated

Clear Eyes

Reason Failed Impurities Specification: Out-of-specification (OOS) stability test result was obtained for unspecified impurity.

Teva Pharmaceuticals USA Inc NDC 67172-504-01 D-0469-2023
Class II · Moderate risk Terminated

Carbidopa and Levodopa Tablets

Reason Packaging defect: observed packaging defect, blister packaging inadequately sealed.

The Harvard Drug Group NDC 0904-7257-61 D-0432-2023
Class II · Moderate risk Terminated

Sterile Water for Injection

Reason CGMP Deviations: Potential product carryover.

Nephron Sc Inc NDC 0487-6105-01 D-0364-2023
Class II · Moderate risk Terminated

Metformin hydrochloride Extended-Release Tablets

Reason CGMP Deviations: Detection of N-Nitrosodimethylamine (NDMA) levels in excess of the Acceptable Daily Intake Limit.

Teva Pharmaceuticals USA Inc NDC 00591-2720-60 D-0441-2023